|Home | About | Journals | Submit | Contact Us | Français|
Volume 58, no. 8, 4682–4689, 2014, https://doi.org/10.1128/AAC.02405-14. Due to ongoing work with arylimidamide-azole combinations, we reexamined the data summarized in Table 2 from this publication. Errors were found in the IC50 value reported for DB766 against L. donovani axenic amastigotes in experiment 2 and in the fitting of some of the individual curves used to arrive at the results expressed in the left-hand side of Table 2. Reanalysis of the original data resulted in the determination of IC50 values of 0.40 μM and 1.7 μM for DB766, IC50 values of 7.3 and 10 μM for posaconazole, and mean ∑FIC values of 0.70 ± 0.17 and 0.44 ± 0.06 in experiments 1 and 2, respectively. In the recalculation of the IC50 value of DB766 in experiment 1, the data point at the lowest concentration of DB766 was excluded due to an absorbance value similar to the no-cell control (likely due to evaporation in the edge well). All IC50 values were recalculated as absolute IC50s to account for dose-response curves where the upper asymptotes did not reach the positive control (no drug) values. The senior author apologizes for the need for this correction and takes responsibility for it.